Abstract
Leuprorelin (leuprolide) acetate, a highly active agonist of luteinizing hormone-releasing hormone (LH-RH) has been widely accepted as a representative agent utilizing drug delivery system. A single injection of this one-month or three-month depot provides persistent drug release, which has been applied to therapy in patients with prostate cancer, breast cancer, endometriosis, myoma uteri, and central precocious puberty. The profile of this drug from basic research to clinical application was reviewed.
